Back A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® CRM Announces Change in Strategic Direction for Japan CRM Market and End of Distribution Agreement with JLL in One Year's Time

[2018-08-30] 

Shanghai, China – August 30, 2018. MicroPort® CRM announces today a change in strategic direction for the CRM market in Japan. With its Japan distributor Japan Lifeline Co., Ltd. ("JLL"), the parties have agreed to end its distribution agreement for the Japan market in one year's time on August 31, 2019. This strategic decision impacts patients, clinicians, hospital customers and employees. As such, both MicroPort® CRM and JLL are committed to working with its key stakeholders to minimize any potential disruptions.
 
Both MicroPort® CRM and JLL commit to current and prospective patients, clinicians and hospitals that there will be uninterrupted service and products available to all patients and hospitals. As it has for the previous 11 years, JLL will continue to service MicroPort® CRM patients until August 31, 2019. After August 31, 2019, MicroPort® CRM will take over commercializing the MicroPort® CRM portfolio of products in Japan. Importantly, all patients implanted with MicroPort® CRM pacemaker and ICD devices (formerly LivaNova and previous to that Sorin) will be able to continue their follow-up with MicroPort® CRM after August 31, 2019.
 
On April 30, 2018, MicroPort® CRM formally closed its acquisition of the CRM business from LivaNova PLC.
 
For patients and clinicians in Japan, please contact your local JLL representative for additional information.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2018 MicroPort Scientific Corporation

CONTACT:
Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6953
Email: ir@microport.com

 

[Prev]:FIREHAWK® CLINICAL DATA FROM THE TARGET AC EUROPEAN CLINICAL TRIAL HAS BEEN ACCEPTED FOR PUBLICATION IN THE PRESTIGIOUS MEDICAL JOURNAL THE LANCET
[Next]:FONTUS™ Single-branched Stent Graft System in Surgical Operation Enters "Green Path", Making the 14th among the Products of MicroPort®